Skip to main navigation Skip to search Skip to main content

Valacyclovir for the prevention of cytomegalovirus infection after kidney transplantation

  • Kotry Study Group
  • Kyung Hee University
  • National Evidence-based Healthcare Collaborating Agency
  • The Catholic University of Korea
  • Korea University
  • Keimyung University
  • Pusan National University
  • Seoul National University
  • Yonsei University
  • CHA University
  • Samsung Medical Center, Sungkyunkwan university
  • Soonchunhyang University
  • Inje University
  • Chonnam National University
  • Hallym University
  • Yonsei University Wonju College of Medicine
  • Kosin University

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Cytomegalovirus (CMV) infection is a frequent complication after kidney transplantation (KT) and has various effects on recipient and graft survival. Although guidelines recommend anti-viral prophylaxis with ganciclovir or valganciclovir, there is a demand for alternative regimen for CMV prevention. We investigated the effects of a 3-month valacyclovir-based prophylaxis on CMV infection and clinical outcomes in KT recipients using a nationwide cohort. Methods: Overall, 2,584 KT recipients from 20 transplant centers registered with the Korean Organ Transplantation Registry between May 2014 and December 2019 were analyzed in this study. The recipients were divided into valacyclovir prophylaxis and non-prophylaxis groups, a 1:3 propensity score matching was performed, and 1,036 recipients (291 and 745 in the prophylaxis and non-prophylaxis groups, respectively) were analyzed. The impact of valacyclovir-based prophylaxis on CMV after KT, other clinical outcomes, and the risk factors for CMV infection development were investigated. Results: The prophylaxis group showed a lower incidence of CMV infection and rejection compared to the non-prophylaxis group (3.64 vs. 10.25 events/100 person-years and 1.85 vs. 7.27 events/100 person-years, respectively). Valacyclovir prophylaxis, donor age, deceased donor, length of hospitalization after KT, anti-thymocyte globulin use, and CMV serological mismatch between the donor and recipient were independent risk factors for CMV infection after KT. Conclusions: Valacyclovir prophylaxis after KT significantly reduced CMV infection and rejection. We suggest that valacyclovir could be considered as an alternative strategy for CMV prophylaxis after KT. However, our study has limitations, including its retrospective design, variability in valacyclovir dosing and CMV monitoring, and unassessed confounding factors. Further prospective studies with standardized protocols and larger cohorts are needed to validate our findings.

Original languageEnglish
Article number314
JournalBMC Infectious Diseases
Volume25
Issue number1
DOIs
StatePublished - Dec 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cytomegalovirus
  • Kidney transplantation
  • Valacyclovir

Fingerprint

Dive into the research topics of 'Valacyclovir for the prevention of cytomegalovirus infection after kidney transplantation'. Together they form a unique fingerprint.

Cite this